Ginkgo Bioworks Inc.
9.18
0.62 (7.24%)
At close: Jan 15, 2025, 9:40 AM
undefined%
Bid 9.22
Market Cap 527.66M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -12.89
PE Ratio (ttm) -0.71
Forward PE n/a
Analyst Sell
Ask 9.29
Volume 92,733
Avg. Volume (20D) 1,286,185
Open 8.99
Previous Close 8.56
Day's Range 8.99 - 9.26
52-Week Range 5.26 - 64.40
Beta undefined

About DNA

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Bi...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 19, 2021
Employees 1,218
Stock Exchange NYSE
Ticker Symbol DNA

Analyst Forecast

According to 5 analyst ratings, the average rating for DNA stock is "Sell." The 12-month stock price forecast is $10, which is an increase of 8.93% from the latest price.

Buy 20.00%
Hold 20.00%
Sell 60.00%
Stock Forecasts

Next Earnings Release

Ginkgo Bioworks Inc. is scheduled to release its earnings on Feb 27, 2025, after market closes.
Analysts project revenue of $44.43M, reflecting a 27.84% YoY growth and earnings per share of -2.44, making a -44.55% decrease YoY.
2 months ago · Source
-4.22%
Ginkgo Bioworks shares are trading higher after th... Unlock content with Pro Subscription
4 months ago · Source
+9.31%
Ginkgo Bioworks shares are trading higher after the company announced it launched a protein LLM and model API build on Google Cloud to accelerate drug development.